Bipolar Disorder Interactive Interpreter

Young Mania Rating Scale (YMRS): Scoring and Cutoffs

The YMRS (Young Mania Rating Scale) is an 11-item clinician-rated scale that measures the severity of manic symptoms over the preceding 48 hours, mainly in bipolar disorder (Young et al., 1978). Totals run 0–60, with CGI-S-linked bands of ≤11 minimal, 12–19 mild, 20–29 moderate, 30–39 markedly severe and ≥40 extremely severe (Samara et al., 2023).

YMRS Score Interpreter

Minimal / remission range

Scores below the remission threshold. Persistent low-level symptoms may still warrant clinical monitoring.

11 items; items 5, 6, 8, 9 scored 0–8 (double-weighted); remaining items 0–4. Higher scores indicate greater manic symptom severity. Clinician-administered over the preceding 48 hours.

Total scoreInterpretation
40+Extremely severeCorresponds to 'severely to most extremely ill' on the CGI-S. Scores in this range were associated with the most impaired patients across 8 randomized controlled trials.
30–39Markedly severeCorresponds to 'markedly ill' on the CGI-S. Typical range associated with acute manic episodes requiring intensive treatment.
20–29ModerateCorresponds to 'moderately ill' on the CGI-S. A score of 20 is the common entry threshold for acute mania trials (Lukasiewicz et al., 2013).
12–19MildCorresponds to 'mildly ill' on the CGI-S. A score ≤12 is the widely cited remission threshold in clinical trials (Patel et al., 2007).
0–11Minimal / remission rangeScores below the remission threshold. Persistent low-level symptoms may still warrant clinical monitoring.

Samara MT, Levine SZ, Leucht S. Pharmacopsychiatry. 2023;56(1):18–24. YMRS–CGI-S equipercentile linkage (N=2,988 across 8 randomized trials). Score anchors correspond to CGI-S severity levels. Educational reference only — not a diagnostic tool.

For reference only — not an assessment, diagnosis, or medical advice. This page provides scoring reference material; interpretation and clinical decisions rest with a qualified clinician.

The YMRS is the criterion-standard 11-item clinician-administered scale for measuring manic symptom severity in bipolar disorder. Validated in 100+ clinical trials and translated into 40+ languages.

What the YMRS measures

The YMRS (Young Mania Rating Scale) is an 11-item clinician-administered rating scale for manic symptom severity developed by Young, Biggs, Ziegler, and Meyer (1978) at the Medical College of Virginia. It is the most widely used mania outcome measure in clinical trials and psychiatric practice worldwide, endorsed by major guidelines for assessing and tracking bipolar I mania.

Items cover the core domains of a manic episode: elevated mood, increased motor activity, sexual interest, reduced sleep, irritability, pressured speech, thought disorder, grandiose content, disruptive behaviour, appearance changes, and impaired insight. Seven items are scored 0–4; four items (irritability, speech, content, and disruptive-aggressive behaviour) are weighted and scored 0–8 due to their greater clinical significance. Total scores range from 0 to 60.

Although originally designed for clinician administration, the YMRS is increasingly used as a self-report (patient-rated) measure in clinical research settings. Patient-rated versions show acceptable convergent validity with clinician-rated scores, particularly for mild-to-moderate mania.

How to administer the YMRS

The YMRS is designed for clinician administration and requires clinical judgment for accurate scoring - particularly for items like thought disorder, content (delusions/hallucinations), and disruptive-aggressive behaviour. Each item is rated over the past 48 hours (or since last assessment). Items 5, 6, 8, and 9 are weighted double (scored 0-8; remaining items 0-4). Score range: 0-60.

Educational and training purposes only. Not a substitute for trained clinician assessment.

YMRS scoring and interpretation

Total score = sum of all 11 items (items 5, 6, 8, 9 scored 0-8; remaining items 0-4). Score range: 0-60. Use the score interpreter above to look up the severity band; the band anchors come from an equipercentile linkage of YMRS scores to CGI-S ratings in 2,988 trial participants (Samara et al., 2023).

Minimum Clinically Important Difference (MCID)

A change of ≥5–6 points on the YMRS is generally considered clinically meaningful in treatment trials. Response is often defined as ≥50% reduction from baseline; remission as a score ≤12. These thresholds vary by study protocol and clinical context.

Psychometric properties

  • Original study (Young et al., 1978): Interrater correlation was 0.93 for the total score and 0.66 to 0.92 for individual items. Scores correlated highly with an independent global rating and with two other mania scales, correlated with subsequent length of hospital stay, and distinguished patients before and after two weeks of treatment.
  • Severity threshold and MCSD (Lukasiewicz et al., 2013): In 3,459 patients with acute manic or mixed states, the optimal threshold for marked severity was 25, and the minimal clinically significant difference was 6.6 points.
  • CGI-S linkage (Samara et al., 2023): In 2,988 participants from eight randomized trials, YMRS scores of about 6, 12, 20, 30, 40 and 52 corresponded to borderline, mildly, moderately, markedly, severely and among the most extremely ill on the CGI-S.
  • Adolescents (Patel et al., 2007): In 99 adolescents with acute mania, a reduction of 55% or more was the optimal response cutoff and an endpoint score of 12 or less the optimal remission cutoff.

Limitations

  • Not a diagnosis. The YMRS measures current manic symptom severity; it does not diagnose bipolar disorder.
  • Requires clinical judgement. Items such as thought disorder, content and disruptive-aggressive behaviour need a trained rater.
  • Thresholds vary. Remission (≤12, sometimes ≤8), response (≥50% or ≥55% reduction) and severity thresholds differ between studies and populations.
  • Short window. Ratings cover the preceding 48 hours, so a single score reflects current state only.
  • Mania only. It does not assess depressive symptoms; pair it with a depression measure in bipolar disorder.

YMRS Item Structure

The YMRS covers 11 symptom domains. Four items are weighted double (scored 0–8) to reflect their clinical importance in distinguishing mania severity.

YMRS vs MDQ for Bipolar Assessment

The YMRS and MDQ serve different purposes in bipolar disorder assessment, one measures current mania severity, the other screens for lifetime bipolar disorder history.

Measuring mania in HiBoop

HiBoop does not offer the YMRS; this page is reference material. For bipolar screening, HiBoop offers the MDQ and HCL-33, with automated scoring and tracking over time.

For reference only — not an assessment, diagnosis, or medical advice. This page provides scoring reference material; interpretation and clinical decisions rest with a qualified clinician.

HiBoop does not offer this scale. This page is reference material.This library is an academic and clinical reference. A scale described here is not necessarily offered in HiBoop; each page says whether it is.

Frequently Asked Questions

Is the YMRS clinician-administered or a self-report measure?

The YMRS is a clinician-administered rating scale. Accurate scoring of several items — such as thought disorder, grandiose content, and disruptive-aggressive behaviour — requires clinical judgment that cannot be reliably replaced by patient self-report. Self-report adaptations exist in the research literature but are not the standard administration format.

What YMRS score indicates remission from mania?

A total score of ≤12 is the most widely cited threshold for remission, supported by signal detection analyses comparing YMRS scores against clinician global impression ratings. Some protocols use ≤8 as a stricter criterion. These thresholds are outcome conventions used in clinical trials and should be interpreted within the broader clinical picture.

How is the YMRS scored?

Eleven items are rated over the preceding 48 hours. Seven items are scored on a 0–4 scale. Four items — irritability, speech, thought content, and disruptive-aggressive behaviour — are weighted and scored 0–8 to reflect their greater clinical significance in distinguishing mania severity. Total scores range from 0 to 60.

Can the YMRS be used to diagnose bipolar disorder?

No. The YMRS measures the current severity of manic symptoms; it does not provide a diagnosis of bipolar disorder or any other condition. Diagnosis requires comprehensive clinical evaluation according to established diagnostic criteria. The YMRS is used to track symptom severity over time and to assess treatment response.

Bill this assessment

The Young Mania Rating Scale (YMRS): Scoring and Cutoffs qualifies for reimbursement under these CPT codes (US).

What's Next

Measurement-based care in practice

For clinicians

HiBoop does not offer this scale. For the scales it does offer, HiBoop automates delivery, scoring and longitudinal tracking across your patient panel.

For individuals

This page is a clinical reference, not a diagnostic tool. If you have concerns about your own symptoms, bring this information to a qualified mental health professional.

References

  1. 1.
    Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435.View source
  2. 2.
    Patel NC, Patrick DM, Youngstrom EA, Strakowski SM, DelBello MP. Response and remission in adolescent mania: signal detection analyses of the Young Mania Rating Scale. J Am Acad Child Adolesc Psychiatry. 2007;46(5):628-635.View source
  3. 3.
    Samara MT, Levine SZ, Leucht S. Linkage of Young Mania Rating Scale to Clinical Global Impression Scale to Enhance Utility in Clinical Practice and Research Trials. Pharmacopsychiatry. 2023;56(1):18-24.View source
  4. 4.
    Lukasiewicz M, Gerard S, Besnard A, et al. Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res. 2013;22(1):46-58.View source

Last reviewed: Jun 3, 2026